Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (281-290 of 301) with videos related to

Pageof 31
Sort By:
Human Gene Therapy|August 1, 1994
Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II studyN Cascinelli, R Foà, G Parmiani, et al.
Human Gene Therapy|September 1, 1994
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.
The Journal of Experimental Medicine|September 8, 1999
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesionsA Anichini, A Molla, R Mortarini, et al.
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|October 1, 1985
Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virusG Carbone, M A Pierotti, M Boiocchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Oncogene|February 8, 2006
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanomaM Sensi, G Nicolini, C Petti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Blood|September 1, 1993
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha proteinS Dermime, F Grignani, M Clerici, et al.
Pageof 31

Showing results (281-290 of 301) with videos related to

Sort By:
Pageof 31
Human Gene Therapy|August 1, 1994
Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II studyN Cascinelli, R Foà, G Parmiani, et al.
Human Gene Therapy|September 1, 1994
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.
The Journal of Experimental Medicine|September 8, 1999
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesionsA Anichini, A Molla, R Mortarini, et al.
The Journal of Clinical Investigation|October 1, 1996
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.
Cancer Research|October 1, 1985
Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virusG Carbone, M A Pierotti, M Boiocchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.
Oncogene|February 8, 2006
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanomaM Sensi, G Nicolini, C Petti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocolsM A Player, K C Barracchini, T B Simonis, et al.
Blood|September 1, 1993
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha proteinS Dermime, F Grignani, M Clerici, et al.
Pageof 31